📊 ATYR Key Takeaways
Investment Thesis
aTYR Pharma is a pre-revenue stage biotech company with minimal commercialization progress and severe financial deterioration. The company is burning cash at an unsustainable rate ($62M operating cash outflow) while generating only $190K in revenue, indicating clinical-stage operations with no meaningful product commercialization. At current burn rates, the company has limited runway and faces imminent capital requirements.
ATYR Strengths
- Strong liquidity position with 5.3x current ratio providing near-term operational flexibility
- Conservative leverage with 0.04x debt-to-equity ratio indicating low financial risk from debt obligations
- Modest stockholders' equity base of $67.5M provides some capital cushion for continued R&D investment
ATYR Risks
- Extreme cash burn of $62M annually with only $10.7M cash on hand, providing less than 2 months of runway at current burn rates
- Negligible revenue of $190K indicates no viable commercial products and complete dependence on capital markets for funding
- Massive net losses of $74.1M representing -39,009.5% net margin, demonstrating fundamental unprofitability and inability to achieve commercialization milestones
- Operating cash flow deficit of $62M annually with negative free cash flow margin of -32,664.7% indicates unsustainable business model
- High insider trading activity (6 Form 4 filings in 90 days) may signal management concern about company trajectory
Key Metrics to Watch
- Cash burn rate and cash runway remaining before next financing requirement
- Revenue growth trajectory and progress toward commercial viability
- R&D spending efficiency and clinical trial advancement status
- Quarterly cash position and liquidity levels
- Insider trading patterns and management confidence indicators
ATYR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.30x current ratio provides a solid financial cushion.
ATYR Profitability Ratios
ATYR vs Healthcare Sector
How aTYR PHARMA INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
ATYR Balance Sheet & Liquidity
ATYR 5-Year Financial Trend
5-Year Trend Summary: aTYR PHARMA INC's revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-0.94 indicates the company is currently unprofitable.
ATYR Growth Metrics (YoY)
ATYR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$17.3M | $-0.23 |
| Q2 2025 | N/A | -$16.3M | $-0.22 |
| Q1 2025 | N/A | -$14.9M | $-0.17 |
| Q3 2024 | N/A | -$11.3M | $-0.20 |
| Q2 2024 | N/A | -$12.3M | $-0.22 |
| Q1 2024 | N/A | -$12.0M | $-0.23 |
| Q3 2023 | N/A | -$11.3M | $-0.20 |
| Q3 2021 | $148.0K | -$6.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ATYR Capital Allocation
ATYR SEC Filings
Access official SEC EDGAR filings for aTYR PHARMA INC (CIK: 0001339970)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATYR
What is the AI rating for ATYR?
aTYR PHARMA INC (ATYR) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATYR's key strengths?
Strong liquidity position with 5.3x current ratio providing near-term operational flexibility. Conservative leverage with 0.04x debt-to-equity ratio indicating low financial risk from debt obligations.
What are the risks of investing in ATYR?
Extreme cash burn of $62M annually with only $10.7M cash on hand, providing less than 2 months of runway at current burn rates. Negligible revenue of $190K indicates no viable commercial products and complete dependence on capital markets for funding.
What is ATYR's revenue and growth?
aTYR PHARMA INC reported revenue of $190.0K.
Does ATYR pay dividends?
aTYR PHARMA INC does not currently pay dividends.
Where can I find ATYR SEC filings?
Official SEC filings for aTYR PHARMA INC (CIK: 0001339970) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATYR's EPS?
aTYR PHARMA INC has a diluted EPS of $-0.80.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.